JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 138 filers reported holding JUNO THERAPEUTICS INC in Q3 2015. The put-call ratio across all filers is 2.12 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $3,009,000 | -49.4% | 65,843 | -50.3% | 0.01% | -57.9% |
| Q3 2017 | $5,947,000 | +42.0% | 132,558 | -5.4% | 0.02% | +26.7% |
| Q2 2017 | $4,187,000 | +620.7% | 140,065 | +434.6% | 0.02% | +400.0% |
| Q1 2017 | $581,000 | -81.6% | 26,200 | -84.3% | 0.00% | -76.9% |
| Q4 2016 | $3,150,000 | +204.6% | 167,082 | +384.6% | 0.01% | +160.0% |
| Q3 2016 | $1,034,000 | -45.4% | 34,475 | -30.1% | 0.01% | -44.4% |
| Q2 2016 | $1,894,000 | -21.5% | 49,299 | -22.2% | 0.01% | -30.8% |
| Q1 2016 | $2,413,000 | +169.0% | 63,371 | +210.6% | 0.01% | +160.0% |
| Q4 2015 | $897,000 | +75.2% | 20,400 | +62.1% | 0.01% | +66.7% |
| Q3 2015 | $512,000 | -91.9% | 12,581 | -89.4% | 0.00% | -92.7% |
| Q2 2015 | $6,306,000 | +201.1% | 118,251 | +242.5% | 0.04% | +156.2% |
| Q1 2015 | $2,094,000 | +379.2% | 34,523 | +312.2% | 0.02% | +433.3% |
| Q4 2014 | $437,000 | – | 8,375 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |